ProPhase Labs, Inc. Repayments of Notes Payable
ProPhase Labs, Inc. (PRPH) reported Repayments of Notes Payable of $182.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfNotesPayable · last filed 2026-08-19
- ProPhase Labs, Inc. repayments of notes payable for the quarter ending 2026-06-30 was $138.00K, a 86.23% decline year-over-year.
- ProPhase Labs, Inc. repayments of notes payable for the quarter ending 2026-03-31 was $44.00K, a 97.08% decline year-over-year.
- ProPhase Labs, Inc. repayments of notes payable for the quarter ending 2025-12-31 was $218.00K, a 87.59% decline year-over-year.
- ProPhase Labs, Inc. repayments of notes payable for the quarter ending 2025-09-30 was $1.50M, a 6.17% decline year-over-year.
- ProPhase Labs, Inc. repayments of notes payable for fiscal 2025 was $4.23M, a 0.35% decline from fiscal 2024.
- ProPhase Labs, Inc. repayments of notes payable for fiscal 2024 was $4.25M.
- ProPhase Labs, Inc. repayments of notes payable for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- ProPhase Labs, Inc. repayments of notes payable for fiscal 2022 was $7.04M, a 15553.33% increase from fiscal 2021.
| Period end | Repayments of Notes Payable 3 month | Repayments of Notes Payable 3 month as first filed | Repayments of Notes Payable 6 month | Repayments of Notes Payable 6 month as first filed | Repayments of Notes Payable 9 month | Repayments of Notes Payable 9 month as first filed | Repayments of Notes Payable 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $138.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $182.00K 10-Q · filed 2026-08-19 | $400.00K derived: sum of 3 quarters · filed 2026-08-19 | $1.91M derived: sum of 4 quarters · filed 2026-08-19 | |||
| 2026-03-31 | $44.00K 10-Q/A · filed 2026-07-09 | $262.00K derived: sum of 2 quarters · filed 2026-07-09 | $1.77M derived: sum of 3 quarters · filed 2026-07-09 | $2.77M derived: sum of 4 quarters · filed 2026-08-19 | |||
| 2025-12-31 | $218.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $1.72M derived: sum of 2 quarters · filed 2026-06-01 | $2.73M derived: sum of 3 quarters · filed 2026-08-19 | $4.23M 10-K · filed 2026-06-01 | |||
| 2025-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $2.51M derived: sum of 2 quarters · filed 2026-08-19 | $4.02M 10-Q · filed 2025-11-19 | $5.77M derived: sum of 4 quarters · filed 2026-08-19 | |||
| 2025-06-30 | $1.00M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $2.51M 10-Q · filed 2026-08-19 | $4.27M derived: sum of 3 quarters · filed 2026-08-19 | $5.87M derived: sum of 4 quarters · filed 2026-08-19 | |||
| 2025-03-31 | $1.51M 10-Q/A · filed 2026-07-09 | $3.27M derived: sum of 2 quarters · filed 2026-07-09 | $4.87M derived: sum of 3 quarters · filed 2026-07-09 | $5.57M derived: sum of 4 quarters · filed 2026-07-09 | |||
| 2024-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $3.36M derived: sum of 2 quarters · filed 2026-06-01 | $4.06M derived: sum of 3 quarters · filed 2026-06-01 | $4.25M 10-K · filed 2026-06-01 | |||
| 2024-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $2.31M derived: sum of 2 quarters · filed 2025-11-19 | $2.49M 10-Q · filed 2025-11-19 | $2.51M 10-Q · filed 2024-11-13 | $2.49M derived: sum of 4 quarters · filed 2025-11-19 | ||
| 2024-06-30 | $703.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $888.00K 10-Q · filed 2025-08-13 | $898.00K 10-Q · filed 2024-08-14 | $888.00K derived: sum of 3 quarters · filed 2025-08-13 | $888.00K derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $185.00K 10-Q · filed 2025-05-20 | $189.00K 10-Q · filed 2024-05-10 | $185.00K derived: sum of 2 quarters · filed 2025-05-20 | $185.00K derived: sum of 3 quarters · filed 2025-05-20 | $185.00K derived: sum of 4 quarters · filed 2025-05-20 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $0.00 derived: sum of 2 quarters · filed 2025-04-01 | $0.00 derived: sum of 3 quarters · filed 2025-04-01 | $0.00 10-K · filed 2025-04-01 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | $5.60M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | $5.60M derived: sum of 3 quarters · filed 2024-08-14 | $5.60M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | $5.60M derived: sum of 2 quarters · filed 2024-05-10 | $5.60M derived: sum of 3 quarters · filed 2024-05-10 | $5.62M derived: sum of 4 quarters · filed 2024-05-10 | |||
| 2022-12-31 | $5.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $5.60M derived: sum of 2 quarters · filed 2024-03-29 | $5.62M derived: sum of 3 quarters · filed 2024-03-29 | $7.04M 10-K · filed 2024-03-29 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $18.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.44M 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $1.44M 10-Q · filed 2023-08-11 | |||||
| 2022-03-31 | $1.43M 10-Q · filed 2023-05-12 | ||||||
| 2021-12-31 | $45.00K 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |